These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21777638)

  • 21. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
    Sun W; Cunningham D; Wasserman SS; Perry J; Putnak JR; Eckels KH; Vaughn DW; Thomas SJ; Kanesa-Thasan N; Innis BL; Edelman R
    Hum Vaccin; 2009; 5(1):33-40. PubMed ID: 18670195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation.
    ; Bentsi-Enchill AD; Schmitz J; Edelman R; Durbin A; Roehrig JT; Smith PG; Hombach J; Farrar J
    Vaccine; 2013 May; 31(23):2603-9. PubMed ID: 23570986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dengue vaccine: a valuable asset for the future.
    Jindal H; Bhatt B; Malik JS; S K S
    Hum Vaccin Immunother; 2014; 10(8):2245-6. PubMed ID: 25424928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targets and strategies for vaccine development against dengue viruses.
    Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
    Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
    Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
    J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
    Yang Y; Meng Y; Halloran ME; Longini IM
    Clin Infect Dis; 2018 Jan; 66(2):178-184. PubMed ID: 29020332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
    Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tropical diseases. Hunt for dengue vaccine heats up as the disease burden grows.
    Normile D
    Science; 2007 Sep; 317(5844):1494-5. PubMed ID: 17872423
    [No Abstract]   [Full Text] [Related]  

  • 31. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
    Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
    Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccines and immunization strategies for dengue prevention.
    Liu Y; Liu J; Cheng G
    Emerg Microbes Infect; 2016 Jul; 5(7):e77. PubMed ID: 27436365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
    Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
    Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine.
    Halstead SB
    Hum Vaccin Immunother; 2018; 14(9):2158-2162. PubMed ID: 29482433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DENGUE VACCINES.
    Thisyakorn U; Thisyakorn C
    Southeast Asian J Trop Med Public Health; 2015; 46 Suppl 1():138-45. PubMed ID: 26506740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice.
    Fuchs J; Chu H; O'Day P; Pyles R; Bourne N; Das SC; Milligan GN; Barrett AD; Partidos CD; Osorio JE
    Vaccine; 2014 Nov; 32(48):6537-43. PubMed ID: 25239488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
    Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
    Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.